$422,315,784

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactive

ACTION DATE2026-03-23·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50119C00037_7505_-NONE-_-NONE-

Award description

VIGIV BUY AND ASSOCIATED SERVICES

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Purchase of VIGIV (Vaccinia Immune Globulin) and associated services for emergency preparedness and response.

Sub-sectors

vaccinespandemic-preparednessbiologics-manufacturing

Why this matters

VIGIV is a critical countermeasure for orthopoxvirus infections; this large stockpile investment strengthens U.S. biodefense capabilities against potential biological threats.

Supply-chain signal

Signals sustained demand for specialized immunoglobulin manufacturing and cold-chain logistics; may incentivize domestic production capacity expansion.

U.S.–China competition angle

Reflects U.S. strategic autonomy in critical biologics; reduces reliance on foreign sources for pandemic/biodefense countermeasures.

Generated by award_classification v1.0.0 via claude-haiku-4-5-20251001 on 2026-05-14. Cost: $0.001488.

Period of performance

Start

2019-05-31

End

2027-03-30

Status

activein 319 days

Sources

Award record ingested from usaspending. Source identifier CONT_AWD_75A50119C00037_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.